ClinicalTrials.gg
CompletedNCT00492297Updated Oct 31, 2014Results posted

A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma

A Phase 2 interventional study of Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC) in Melanoma, sponsored by Bayer. Completed at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-31.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing dacarbazine in Melanoma — none open to participants now, 1 under way, none of them phase 3. Dacarbazine · Melanoma.

Enrollment
11th of 25
83 · median 64
Started
2005
with 2 others
Phase 2
14 of 30
none open now
Registered
11th of 30
by date
Lead sponsor
1 of 30
Bayer

Among the 30 studies testing dacarbazine in Melanoma, this one is the 11th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2005, is one of 14 in phase 2, and was the 11th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 30 studies testing dacarbazine in Melanoma is open now. The open studies under Melanoma, anywhere →

About dacarbazine

Dacarbazine: first FDA approval 1975 (DTIC-DOME). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies testing dacarbazine in Melanoma as a file.
02

Study summary

The purpose of this study is to see whether a new type of anti-cancer drug, known as BAY 43-9006, can be given safely and with good effect in combination with dacarbazine (DTIC). DTIC is the current standard chemotherapy drug given for melanoma that has spread through the body. Although this drug can be effective on its own and is generally well tolerated, not all patients will benefit, so there is a need to test new drugs and drug combinations for treating melanoma.

Read the detailed description

Issues on "Safety" outcomes are addressed in the Adverse Event section.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with advanced, , confirmed melanoma, for whom treatment with dacarbazine is considered medically acceptable
  • Age >= 18 years
  • Subject has measurable and evaluable disease defined as at least one metastatic lesion that can be accurately and serially measured by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan as per the (RECIST) criteria. Cutaneous lesions measuring at least 20mm in longest diameter can be considered measurable (and therefore target lesions) via color photography including a ruler
  • Subject has biopsiable disease at baseline and is willing to provide samples, or does not have biopsiable disease at baseline
  • (ECOG) Performance Status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Primary ocular or mucosal melanoma (cutaneous vulval melanoma is permitted)
  • Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors [Ta, Tis \& T1] or any cancer curatively treated > 3 years prior to study entry
  • (Active coronary artery disease or ischemia (myocardial infarction more than 6 months prior to study entry is allowed)
  • Uncontrolled hypertension (> grade 2 National Cancer Institute - (NCI-CTCAE) version 3.0)
  • Active, clinically serious infections (> grade 2 NCI-CTCAE version 3.0)
  • Subjects with seizure disorder requiring medication are excluded
  • History of or suspected (HIV) infection, or chronic or C
  • Symptomatic brain or meningeal tumors unless the subject is > 6 months from definitive therapy, has a negative imaging study within 4 weeks prior to study entry and is clinically stable with respect to the tumor at the time of study entry. Also the subject must not be undergoing acute therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for one month prior to and following screening radiographic studies)
  • Pregnant or breast-feeding subjects
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Sorafenib + Dacarbazine

    Dacarbazine 1000 mg/m\^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)

    Drug: Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)

Interventions

  • DrugSorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)

    Drug page: Dacarbazine

    Dacarbazine 1000 mg/m\^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)

06

What researchers measure

Primary outcomes

  1. Overall Best Response

    Best Overall Response (BOR): Best tumor response achieved during or within 30 days after active therapy confirmed according to the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR): The disappearance of all target and non-target lesions. Partial response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. SD was defined as steady state of disease, PD was defined as an increase of at least 20% increase in the sum of the LD of target lesions or appearance of new lesions.

    Time frame: during or within 30 days after active therapy

Secondary outcomes

  1. Progression-free Survival

    Progression-free Survival (PFS) was the time from the first dose of combination therapy to disease progression (radiological or clinical, whichever is earlier) or death (if death occurs before progression is documented). PFS for subjects without tumor progression or death at the time of analysis were censored at the date of last tumor evaluation.

    Time frame: from start of treatment until progression or death before progression (median 259 days)

  2. Percentage of Subjects With Progression-free Survival at Specific Time-points

    Progression-free Survival (PFS) was the time from the first dose of combination therapy to disease progression (radiological or clinical, whichever is earlier) or death (if death occurs before progression is documented). PFS for subjects without tumor progression or death at the time of analysis were censored at the date of last tumor evaluation.

    Time frame: from start of treatment until progression or death before progression after 3, 6 and 12 months

  3. Overall Survival

    Overall Survival was the number of days from the date that combination treatment started until the date of death.

    Time frame: from start of treatment until death (median 259 days)

  4. Duration of Response

    Duration of Response was assessed in subjects who showed a Partial Response (PR) or Complete Response (CR). It was defined as the time from the first documented objective response to Progressive Disease (PD), or death if before documented progression. Duration of response for subjects who have not progressed or died at the time of analysis was censored at the date of last tumor assessment.

    Time frame: from confirmed Complete Response (CR) or Partial Response (PR) until Progressive Disease (PD) (median 259 days)

  5. Duration of Complete Response

    Duration of complete response was the number of days from the date that a complete response was first documented to the date that recurrent or progressive disease was first objectively documented (if patient progressed then censored=no) or to last observation (if patient did not progress then censored=yes).

    Time frame: from confirmed CR until PD (median 259 days)

  6. Duration of Partial Response

    Duration of partial response was the number of days from the date that a partial response was first documented to the date that recurrent or progressive disease was first objectively documented (if patient progressed then censored=no) or to last observation (if patient did not progress then censored=yes).

    Time frame: from confirmed PR until PD (median 259 days)

  7. Disease Control (DC)

    DC was defined as the total number of subjects whose best response was not progressive disease (PD) (total number of CRs + total number of PRs + total number of Stable Diseases (SD)). The DC at specific time points could also be calculated as the total number of subjects whose response was not PD at that time point.

    Time frame: after start of treatment, at 6 months and 12 months

  8. Duration of Stable Disease

    Duration of Stable Disease (DSD), defined as the time from the first documented objective evidence of Stable Disease (SD) to disease progression (DP) or death if death occurred before DP, was assessed in subjects who showed SD as best response. DSD for subjects who had not progressed or died was censored at the date of last tumor assessment.

    Time frame: from start of therapy to PD, only in non-responders (median 259 days)

  9. Time to Response

    Time to Response in subjects who achieved an objective response (PR or CR with confirmation) was measured from the date of starting study combination treatment until the earliest date that the response was first documented.

    Time frame: start of therapy to confirmed CR or PR (median 259 days)

  10. Time to Progression

    Time to Progression was the number of days from the start of therapy to progression (if patient progressed then censored=no) or to the last observation at which the patient was known to have not progressed, that is, the last observation with a best response of CR, PR, or SD.

    Time frame: From start of treatment until progression (median 259 days)

07

Results

Posted Jan 25, 2011
Limitations and caveats
Due to the small number of patients, no conclusions can be drawn from these data in terms of BRAF mutations.

Participant flow

This study had a 2-stage Simon optimal design consisting of 30 subjects in the first stage and 52 subjects in the second stage for a planned total of 82 subjects. Actually a total of 96 subjects were enrolled and 83 were treated; 32 in the 1st stage and 51 in the second stage. The study was conducted at 8 centers in the UK and 4 centers in France.

Treatment
Participant flow — Treatment
MilestoneSorafenib + Dacarbazine
Started83
First stage of simon optimal design32
Second stage of simon optimal design51
Completed78
Not completed5
Withdrew: Death2
Withdrew: Study terminated by sponsor3
Active Follow-up 30(+4) Days Duration
Participant flow — Active Follow-up 30(+4) Days Duration
MilestoneSorafenib + Dacarbazine
Started78
Completed59
Not completed19
Withdrew: Death17
Withdrew: Study terminated by sponsor2
Survival Only Follow-up
Participant flow — Survival Only Follow-up
MilestoneSorafenib + Dacarbazine
Started59
Completed0
Not completed59
Withdrew: Death46
Withdrew: Lack of efficacy1
Withdrew: Study terminated by sponsor12

Outcome measures

PrimaryOverall Best Response

Best Overall Response (BOR): Best tumor response achieved during or within 30 days after active therapy confirmed according to the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response (CR): The disappearance of all target and non-target lesions. Partial response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. SD was defined as steady state of disease, PD was defined as an increase of at least 20% increase in the sum of the LD of target lesions or appearance of new lesions.

Time frame:
during or within 30 days after active therapy
Reported as:
Number · participants
Overall Best Response
participantsSorafenib + Dacarbazine
Overall response (CR+PR)10
Complete response (CR)1
Partial response (PR)9
Stable disease (SD)31
Progressive disease (PD)34
SecondaryProgression-free Survival

Progression-free Survival (PFS) was the time from the first dose of combination therapy to disease progression (radiological or clinical, whichever is earlier) or death (if death occurs before progression is documented). PFS for subjects without tumor progression or death at the time of analysis were censored at the date of last tumor evaluation.

Time frame:
from start of treatment until progression or death before progression (median 259 days)
Reported as:
Median · days
Progression-free Survival
daysSorafenib + Dacarbazine
Progression-free Survival102 (83 to 134)
SecondaryPercentage of Subjects With Progression-free Survival at Specific Time-points

Progression-free Survival (PFS) was the time from the first dose of combination therapy to disease progression (radiological or clinical, whichever is earlier) or death (if death occurs before progression is documented). PFS for subjects without tumor progression or death at the time of analysis were censored at the date of last tumor evaluation.

Time frame:
from start of treatment until progression or death before progression after 3, 6 and 12 months
Reported as:
Number · percentage of participants
Percentage of Subjects With Progression-free Survival at Specific Time-points
percentage of participantsSorafenib + Dacarbazine
PFS at month 356.63
PFS at month 633.73
PFS at month 1210.84
SecondaryOverall Survival

Overall Survival was the number of days from the date that combination treatment started until the date of death.

Time frame:
from start of treatment until death (median 259 days)
Reported as:
Median · days
Overall Survival
daysSorafenib + Dacarbazine
Overall Survival259 (237 to 322)
SecondaryDuration of Response

Duration of Response was assessed in subjects who showed a Partial Response (PR) or Complete Response (CR). It was defined as the time from the first documented objective response to Progressive Disease (PD), or death if before documented progression. Duration of response for subjects who have not progressed or died at the time of analysis was censored at the date of last tumor assessment.

Time frame:
from confirmed Complete Response (CR) or Partial Response (PR) until Progressive Disease (PD) (median 259 days)
Reported as:
Median · days
Duration of Response
daysSorafenib + Dacarbazine
Duration of Response327 (99 to 628)
SecondaryDuration of Complete Response

Duration of complete response was the number of days from the date that a complete response was first documented to the date that recurrent or progressive disease was first objectively documented (if patient progressed then censored=no) or to last observation (if patient did not progress then censored=yes).

Time frame:
from confirmed CR until PD (median 259 days)
Reported as:
Number · days
Duration of Complete Response
daysSorafenib + Dacarbazine
Duration of Complete Response420
SecondaryDuration of Partial Response

Duration of partial response was the number of days from the date that a partial response was first documented to the date that recurrent or progressive disease was first objectively documented (if patient progressed then censored=no) or to last observation (if patient did not progress then censored=yes).

Time frame:
from confirmed PR until PD (median 259 days)
Reported as:
Median · days
Duration of Partial Response
daysSorafenib + Dacarbazine
Duration of Partial Response255 (231 to 448)
SecondaryDisease Control (DC)

DC was defined as the total number of subjects whose best response was not progressive disease (PD) (total number of CRs + total number of PRs + total number of Stable Diseases (SD)). The DC at specific time points could also be calculated as the total number of subjects whose response was not PD at that time point.

Time frame:
after start of treatment, at 6 months and 12 months
Reported as:
Number · participants
Disease Control (DC)
participantsSorafenib + Dacarbazine
DC based on overall best response41
DC at 6 months38
DC at 12 months38
SecondaryDuration of Stable Disease

Duration of Stable Disease (DSD), defined as the time from the first documented objective evidence of Stable Disease (SD) to disease progression (DP) or death if death occurred before DP, was assessed in subjects who showed SD as best response. DSD for subjects who had not progressed or died was censored at the date of last tumor assessment.

Time frame:
from start of therapy to PD, only in non-responders (median 259 days)
Reported as:
Median · days
Duration of Stable Disease
daysSorafenib + Dacarbazine
Duration of Stable Disease93 (77 to 112)
SecondaryTime to Response

Time to Response in subjects who achieved an objective response (PR or CR with confirmation) was measured from the date of starting study combination treatment until the earliest date that the response was first documented.

Time frame:
start of therapy to confirmed CR or PR (median 259 days)
Reported as:
Median · days
Time to Response
daysSorafenib + Dacarbazine
Time to Response48 (41 to 87)
SecondaryTime to Progression

Time to Progression was the number of days from the start of therapy to progression (if patient progressed then censored=no) or to the last observation at which the patient was known to have not progressed, that is, the last observation with a best response of CR, PR, or SD.

Time frame:
From start of treatment until progression (median 259 days)
Reported as:
Median · days
Time to Progression
daysSorafenib + Dacarbazine
Time to Progression102 (88 to 139)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sorafenib + Dacarbazine—40/83 (48.2%)82/83 (98.8%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventSorafenib + Dacarbazine
Death not associated with CTAE term, disease progression nosGeneral disorders7/83
PlateletsBlood and lymphatic system disorders5/83
Pain, abdomen nosGeneral disorders5/83
FeverGeneral disorders4/83
Thrombosis/thrombus/embolismVascular disorders4/83
HemoglobinBlood and lymphatic system disorders3/83
FatigueGeneral disorders3/83
LeukocytesBlood and lymphatic system disorders2/83
NeutrophileBlood and lymphatic system disorders2/83
Cardiac arrhythmia - otherCardiac disorders2/83
Most frequent other events
Showing 10 of 43
Most frequent other events
EventSorafenib + Dacarbazine
FatigueGeneral disorders51/83
ConstipationGastrointestinal disorders44/83
DiarrheaGastrointestinal disorders43/83
NeutrophilsBlood and lymphatic system disorders42/83
NauseaGastrointestinal disorders38/83
Hand-foot skin reactionSkin and subcutaneous tissue disorders37/83
Rash/desquamationSkin and subcutaneous tissue disorders33/83
PlateletsBlood and lymphatic system disorders24/83
VomitingGastrointestinal disorders24/83
Pain, abdomen nosGeneral disorders24/83

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sorafenib + Dacarbazine
Mean53.5 (25 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)Sorafenib + Dacarbazine
Female33
Male50
Clinical disease status
Clinical disease status(participants)Sorafenib + Dacarbazine
Missing6
Stable disease3
Progressive disease74
Disease stage (AJCC)
Disease stage (AJCC)(participants)Sorafenib + Dacarbazine
Missing1
M1a Distant subcutaneous or lymphnode metastases4
M1b Lung metastases12
M1c All other visceral metastases66
ECOG status
ECOG status(participants)Sorafenib + Dacarbazine
Missing3
052
128
Histology
Histology(participants)Sorafenib + Dacarbazine
Missing24
Malignant melanoma4
Superfical spreading24
Nodular29
Acral lentiginous2
Lactate dehydrogenase
Lactate dehydrogenase(participants)Sorafenib + Dacarbazine
Missing3
< Upper Limit of Normal (ULN=325 U/L)43
>= ULN but < 10 percent above ULN11
>= 10 percent above the ULN26
Mean time from diagnosis
Mean time from diagnosis(days)Sorafenib + Dacarbazine
Mean1280 (9 to 5344)
08

Study locations

12 sites
  • Bordeaux, 33000, France
  • Lyon Cedex, 39373, France
  • Toulouse, 31052, France
  • Villejuif, 94805, France
  • Cambridge, Cambridgeshire CB2 0QQ, United Kingdom
  • Southampton, Hampshire SO16 6YD, United Kingdom
  • Northwood, Middlesex HA6 2RN, United Kingdom
  • Sutton, Surrey SM2 5PT, United Kingdom
  • London, NW3 2QG, United Kingdom
  • London, SE1 7EH, United Kingdom
  • London, SW3 6JJ, United Kingdom
  • Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Eisen T, Marais R, Affolter A, Lorigan P, Robert C, Corrie P, Ottensmeier C, Chevreau C, Chao D, Nathan PD, Jouary T, Harries M, Negrier S, Montegriffo E, Ahmad T, Gibbens I, James MG, Strauss UP, Prendergast S, Gore ME. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br J Cancer. 2011 Jul 26;105(3):353-9. doi: 10.1038/bjc.2011.257. Epub 2011 Jul 12. PubMed 21750549 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Jun 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2007
First posted
Jun 27, 2007
Start
Apr 2005
Primary completionActual
Jun 2008
CompletionActual
Jul 2008
Results first posted
Jan 25, 2011
Last update
Oct 31, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00492297
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 27, 2007
Start date
Apr 2005
Primary completion
Jun 2008
Completion
Jul 2008
Results posted
Jan 25, 2011
Last update
Oct 31, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dacarbazine

Start the discussion